Syndax Pharmaceuticals, Inc. (SNDX) Return on equity 2016–2025
Syndax Pharmaceuticals, Inc. (SNDX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-441.6%FY2025 · since FY2016: -52.9% → -441.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -441.6% | -331.0 pp |
| FY2024 | -110.6% | -72.9 pp |
| FY2023 | -37.8% | -5.8 pp |
| FY2022 | -31.9% | -38.1 pp |
| FY2021 | 6.1% | +35.1 pp |
| FY2020 | -29.0% | +148.4 pp |
| FY2019 | -177.4% | -37.9 pp |
| FY2018 | -139.4% | -81.1 pp |
| FY2017 | -58.3% | -5.4 pp |
| FY2016 | -52.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SNDX financial trends
SNDX RevenueSNDX Net incomeSNDX Net marginSNDX Gross profitSNDX Gross marginSNDX Operating incomeSNDX Operating marginSNDX Operating cash flowSNDX Free cash flowSNDX Capital expendituresSNDX Stock buybacksSNDX Dividends paidSNDX Total assetsSNDX Total liabilitiesSNDX Shareholders’ equitySNDX overview →